Bladder Cancer Stages

Bladder cancer staging describes how deeply a tumor has grown into the bladder wall and whether it has spread to nearby lymph nodes or other parts of the body. Most bladder cancers begin in the urothelium, the thin layer of specialized cells lining the bladder. Determining the stage of the cancer is one of the most important steps in treatment planning because it helps the healthcare team select the most appropriate therapies and estimate the likely course of the disease.

How bladder cancer is staged

Accurate bladder cancer staging begins with a determination of how deeply the tumor extends into the bladder wall and whether cancer cells have spread beyond the bladder. This process relies heavily on direct visualization of the bladder and examination of tissue samples, with imaging providing additional information about the extent of the disease.

The staging evaluation for bladder cancer may include:

• Cystoscopy – A urologist will insert a thin, flexible tube with a miniature camera attached through the urethra and into the bladder. Using the cystoscope, the urologist can examine the bladder lining and identify, measure and biopsy suspicious tissues.
• Transurethral resection of bladder tumor (TURBT) – TURBT is considered the cornerstone of bladder cancer diagnosis and initial staging. During this minimally invasive procedure, the physician will remove the visible tumor through a cystoscope along with a small sample of underlying bladder muscle. A pathologist will then evaluate the removed tissue to determine the tumor grade, how deeply it has invaded the bladder wall and whether muscle invasion is present.
• Repeat TURBT (when appropriate) – For certain high-grade tumors or tumors that have grown into the connective tissue beneath the bladder lining (lamina propria) but have not reached the bladder muscle, a second TURBT may be recommended to confirm the stage, ensure complete tumor removal and identify any previously undetected muscle invasion.
• Cross-sectional imaging – Computed tomography (CT) urography, magnetic resonance imaging (MRI) or other advanced imaging tests may be used to evaluate whether the cancer has extended beyond the bladder into nearby organs, lymph nodes or distant sites. These studies complement—but do not replace—the information obtained through TURBT.
• Additional laboratory testing – Blood work and urinalysis may help evaluate the patient’s overall health and support treatment planning, although these tests do not determine the cancer stage.

After integrating the findings of these tests, the healthcare team will assign an overall stage that reflects the extent of cancer and guides treatment recommendations.

Bladder cancer stages

Bladder cancer staging reflects an anatomical pattern of disease progression, beginning in the bladder’s inner lining and potentially extending through the bladder wall before spreading to nearby structures or distant organs. Understanding the precise location and extent of the cancer can help the healthcare team recommend therapies that offer the best balance of disease control and quality of life.

Stage 0 bladder cancer

Stage 0 bladder cancer remains confined to the urothelium. It has not entered the connective tissue beneath the bladder lining or invaded the bladder muscle. This early stage may be further divided into two categories:

• Stage 0a (noninvasive papillary carcinoma) – The tumor has formed finger-like growths that project into the bladder cavity without growing into the bladder wall.
• Stage 0is (carcinoma in situ or CIS) – A flat, high-grade lesion remains limited to the urothelium but has a greater likelihood of progressing if left untreated.

Because stage 0 tumors have not invaded deeper tissues, treatment generally focuses on preserving the bladder while removing or destroying the cancer and reducing the risk of recurrence. Management typically begins with TURBT. Depending on the type of tumor and its risk of recurrence or progression, treatment may also include intravesical therapy, such as Bacillus Calmette-Guérin (BCG) or chemotherapy delivered directly into the bladder.

Stage 1 bladder cancer

Stage 1 bladder cancer has grown beyond the urothelium into the lamina propria, but it has not invaded the muscularis propria. Although the cancer remains non-muscle-invasive, it has a higher risk of recurrence and progression than stage 0 bladder cancer, particularly if the tumor is high grade, meaning the cancer cells appear very abnormal under a microscope and are more likely to grow and spread aggressively.

Treatment for stage 1 bladder cancer often begins with TURBT, sometimes followed by repeat TURBT to confirm the stage. Intravesical BCG therapy may be recommended for high-risk cancer to reduce the likelihood of recurrence and progression. If the tumor displays particularly aggressive features, the patient may be evaluated for early bladder removal (radical cystectomy).

Stage 2 bladder cancer

Stage 2 bladder cancer has invaded the muscularis propria. Although the cancer remains confined to the bladder, it is classified as muscle-invasive bladder cancer.

Because muscle invasion increases the risk that microscopic cancer cells may be present beyond the bladder, treatment at this stage typically includes therapies designed to address both the tumor in the bladder and potential cancer cells elsewhere in the body. Many eligible patients receive cisplatin-based chemotherapy followed by radical cystectomy with pelvic lymph node dissection. Alternatively, a carefully selected patient may be a candidate for bladder-preserving trimodality therapy, which combines maximal TURBT, chemotherapy and radiation therapy.

Stage 3 bladder cancer

Stage 3 bladder cancer includes several patterns of local or regional spread. The cancer may have grown beyond the bladder muscle into nearby tissues or organs, invaded regional lymph nodes, or both, but it has not spread or metastasized to distant parts of the body. These patterns of spread may include:

• Grown into the layer of fatty tissue surrounding the bladder (perivesical fat)
• Extended into nearby reproductive organs, such as the prostate or seminal vesicles in men or the uterus or vagina in women
• Spread to one or more nearby regional lymph nodes

Treatment for stage 3 bladder cancer typically requires a multimodal approach. Depending on the extent of the cancer and the patient’s overall health, recommendations may include chemotherapy, radical cystectomy, pelvic lymph node dissection, radiation therapy, immunotherapy or a combination regimen. Molecular testing may also be used to help identify patients who could benefit from targeted therapies or antibody-drug conjugates.

Stage 4 bladder cancer

Stage 4 is the most advanced stage of bladder cancer. At this stage, the cancer may have:

• Grown into the pelvic wall or abdominal wall
• Spread to lymph nodes near the common iliac arteries
• Spread to distant lymph nodes or organs, such as the lungs, liver or bones

At stage 4, treatment generally focuses on controlling the cancer throughout the body while relieving symptoms and preserving quality of life. Systemic therapies often play a central role in treating advanced bladder cancer and may include chemotherapy, immune checkpoint inhibitors, targeted therapies and antibody-drug conjugates. Surgery or radiation therapy may also be used in select situations to manage symptoms or treat specific areas of cancer spread. For some patients, clinical trials may provide access to promising investigational therapies that are not yet widely available.

Bladder Cancer Outcomes

The primary aim of cancer treatment is to attain the best possible outcome with minimal side effects, ensuring the highest quality of life for the patient. On average, Moffitt's bladder cancer treatment survival rates are 2.5 times higher than the national average.

Our Outcomes

Prognosis for bladder cancer

When reporting survival statistics, the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program groups bladder cancer into three broad categories:

• Localized – The cancer remains confined to the bladder.
• Regional – The cancer has spread into nearby tissues, organs or regional lymph nodes.
• Distant – The cancer has spread to organs or lymph nodes farther from the bladder.

These categories differ from AJCC stages but provide a useful way to compare long-term outcomes across large populations. In general, localized bladder cancer has a more favorable prognosis than regional or distant disease because it can often be treated before extensive spread occurs.

On average, Moffitt's bladder cancer treatment survival rates are 2.5 times the national average. It is important to remember that SEER statistics describe outcomes from patients treated over many years and cannot predict an individual patient’s prognosis. Survival is influenced by numerous factors, including the tumor’s stage, grade and molecular characteristics as well as the patient’s overall health and response to treatment.

The outlook for patients with advanced bladder cancer continues to improve. Recent advances—including immune checkpoint inhibitors, FGFR-targeted therapies for eligible patients and antibody-drug conjugates such as enfortumab vedotin—have expanded treatment options and improved patient outcomes compared with historical data. Ongoing clinical trials continue to evaluate new combinations of immunotherapy, targeted therapy and other novel agents that may further improve the prognosis for bladder cancer.

The Moffitt Cancer Center difference for bladder cancer staging

An accurate stage is the foundation of an effective bladder cancer treatment plan. At Moffitt, the specialists in our Urologic Oncology Program work together to perform comprehensive staging using advanced endoscopic techniques, expert genitourinary pathology review and sophisticated imaging technologies. Our collaborative approach helps ensure that treatment recommendations are based on the most complete and accurate understanding of each patient’s disease.

For patients who have already been diagnosed and are seeking additional reassurance, Moffitt also provides comprehensive second opinions, including pathology review and multidisciplinary evaluation that may confirm or refine a previously determined diagnosis or stage. 

Moffitt offers the latest diagnostic and treatment options for bladder cancer, including Blue Light Cystoscopy with Cysview (BLCC). Eligible patients may also have access to innovative clinical trials investigating next-generation imaging approaches, precision medicine strategies and novel therapies for both non-muscle-invasive and advanced bladder cancer.

To learn more about bladder cancer staging, you can request an appointment with a specialist at Moffitt by calling 1-888-663-3488 or submitting a new patient registration form online. We do not require referrals.